The agreement gives Innovent Biologics exclusive commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China, as the U.S. pharmaceutical giant adapts to growing generic competition in one of the world’s largest drug markets.
Chinese biopharmaceutical company Innovent Biologics has signed an agreement with Eli Lilly to obtain exclusive commercialization rights for the breast cancer drug Verzenios (Verzenio) in mainland China. The deal allows Innovent to market and distribute the treatment across China, while Eli Lilly will continue to manufacture, supply, and further develop the medicine. Financial terms of the agreement were not disclosed.
The partnership comes as Eli Lilly faces increasing pressure from generic drug manufacturers in China following the approval of a lower-cost generic version of Verzenios. The move reflects a broader trend among multinational pharmaceutical companies to partner with local firms to maintain market presence while navigating changing competitive conditions.
Innovent Gains Exclusive Commercialization Rights
Under the agreement, Innovent Biologics will become solely responsible for commercializing Verzenios throughout mainland China.
Although Innovent will oversee marketing and sales, Eli Lilly will retain responsibility for manufacturing the drug, managing supply, and supporting its ongoing clinical development. The arrangement enables both companies to leverage their respective strengths—Lilly’s research and manufacturing expertise and Innovent’s established commercial network within China’s healthcare system.
Generic Competition Reshapes China’s Drug Market
The agreement follows the approval of a generic version of Verzenios by Chinese pharmaceutical company Qingfeng Pharmaceutical Group, increasing competition for the original product.
Generic medicines typically reduce prices and place pressure on branded drug sales once market exclusivity weakens. Analysts say the licensing agreement allows Eli Lilly to preserve its presence in China while relying on a domestic partner with strong market access and commercial capabilities.
Verzenios Plays Key Role in Breast Cancer Treatment
Verzenios is widely used to treat certain forms of HR-positive, HER2-negative breast cancer, helping slow disease progression and improve patient outcomes.
The medicine has become one of Eli Lilly’s major oncology products worldwide. During the fourth quarter of 2025, Verzenios generated approximately $608 million in revenue outside the United States, highlighting its importance within the company’s global cancer treatment portfolio.
Longstanding Partnership Between Lilly and Innovent
The latest agreement builds upon a strategic partnership that Eli Lilly and Innovent Biologics have maintained for more than a decade.
Since first collaborating in 2015, the two companies have jointly developed and commercialized several therapies for cancer and other diseases. Their relationship has expanded over the years, making Innovent one of Lilly’s key pharmaceutical partners in China.
China’s Oncology Market Continues to Grow
China remains one of the world’s fastest-growing pharmaceutical markets, particularly in oncology.
An aging population, rising cancer diagnoses, improved healthcare access, and greater adoption of innovative medicines have made the country a strategic priority for global drug manufacturers. At the same time, government policies encouraging generic medicines have intensified competition, prompting international companies to adopt new commercialization strategies through partnerships with domestic firms.
Agreement Supports Long-Term Growth Strategy
For Innovent Biologics, the acquisition of Verzenios’ commercialization rights further strengthens its oncology portfolio and expands its presence in China’s competitive pharmaceutical sector.
For Eli Lilly, the partnership provides an opportunity to continue serving Chinese patients while adapting to changing market dynamics and focusing resources on developing next-generation therapies. As competition within China’s pharmaceutical industry continues to increase, collaborations between multinational companies and local biotech firms are expected to become an increasingly important strategy for sustaining growth and expanding patient access to advanced treatments.
